Vaccines and immunization against human papillomavirus

Area of Science:

• Immunology
• Virology
• Oncology

Background:

• Human papillomavirus (HPV) infections are linked to various cancers, necessitating effective immunization and therapeutic strategies.
• Current vaccines offer protection against specific HPV types, but broader cross-protection and therapeutic approaches are needed.
• Persistent HPV infections can evade immune responses, posing challenges for therapeutic interventions.

Purpose of the Study:

• To review advancements in prophylactic and therapeutic immunization strategies for HPV-associated diseases and cancers.
• To highlight the need for improved vaccine immunogens and adjuvants for broader HPV type coverage and cross-protection.
• To discuss challenges and future directions in developing effective immunotherapies for HPV-associated cancers.

Main Methods:

• Review of existing literature on HPV vaccines, immunogens (virus-like particles, capsid, L2), and adjuvants.
• Analysis of preclinical and clinical studies on therapeutic immunization strategies targeting HPV early proteins and capsid antigens.
• Examination of immune responses in HPV-infected hosts and challenges posed by immune evasion mechanisms.

Main Results:

• Current vaccines are effective against matched HPV types; second-generation vaccines aim for broader protection.
• Adjuvants are necessary to enhance the efficacy of broadly cross-protective L2-based immunogens.
• Therapeutic strategies show promise in preclinical models, with some translating to clinical lesion clearance.
• Immune evasion by persistent HPV infections presents significant hurdles for therapeutic interventions.

Conclusions:

• Combination strategies involving prophylactic vaccines and therapeutic immunotherapies may be essential for complete clearance of HPV infections and associated cancers.
• Further understanding of in situ immune responses to HPV lesions is required to optimize T cell-mediated therapies.
• Developing broadly cross-protective vaccines and overcoming immune suppression are key goals for future HPV control.